David Ferry

16.3k total citations · 4 hit papers
126 papers, 9.2k citations indexed

About

David Ferry is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Ferry has authored 126 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 32 papers in Molecular Biology. Recurrent topics in David Ferry's work include Colorectal Cancer Treatments and Studies (44 papers), Gastric Cancer Management and Outcomes (43 papers) and Lung Cancer Treatments and Mutations (24 papers). David Ferry is often cited by papers focused on Colorectal Cancer Treatments and Studies (44 papers), Gastric Cancer Management and Outcomes (43 papers) and Lung Cancer Treatments and Mutations (24 papers). David Ferry collaborates with scholars based in United States, United Kingdom and Germany. David Ferry's co-authors include Hartmut Glossmann, Eric Van Cutsem, David Cunningham, Jaffer A. Ajani, Atsushi Ohtsu, Kei Muro, A. Göll, Josep Tabernero, H. Wilke and G. Bodoky and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David Ferry

126 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations Kei Muro, Eric Van Cutsem et al. profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Ian Chau, David Cunningham et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David Ferry

Since Specialization

Citations

This map shows the geographic impact of David Ferry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ferry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ferry more than expected).

Fields of papers citing papers by David Ferry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ferry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ferry. The network helps show where David Ferry may publish in the future.

Co-authorship network of co-authors of David Ferry

This figure shows the co-authorship network connecting the top 25 collaborators of David Ferry. A scholar is included among the top collaborators of David Ferry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ferry. David Ferry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial 2020 ·Cancers ·Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik‐Tobias Arkenau, Jennifer L. Cultrera, Rafael Santana-Dávila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, Gu Mi, Ling Gao, Samuel McNeely, Joana Oliveira, David Ferry, Roy S. Herbst, Charles S. Fuchs	22
2	Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) 2020 ·Journal of Thoracic Oncology ·David R. Spigel, Robert M. Jotte, John Nemunaitis, (unknown), Jeffrey Schneider, Jerome H. Goldschmidt, (unknown), David Berz, Lasika Seneviratne, (unknown), (unknown), Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin	36
3	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC 2020 ·Journal of Thoracic Oncology ·Roy S. Herbst, (unknown), Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, (unknown), Nicolas Penel, Rafael Santana-Dávila, Helge Bischoff, Ian Chau, Gu Mi, (unknown), Erik Rasmussen, David Ferry, Bo H. Chao, Luis Paz‐Ares	44
4	Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Egbert F. Smit, Edward B. Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B. Cohen, Ling Gao, Lisa M. O’Brien, Pablo Lee, Annamaria H. Zimmermann, David Ferry, Allen S. Melemed, M. Pérol	15
5	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers 2017 ·Clinical Cancer Research ·Paul K. Paik, Ronglai Shen, Michael F. Berger, David Ferry, Jean‐Charles Soria, Alastair Mathewson, Claire Rooney, Neil R. Smith, Marie Cullberg, Elaine Kilgour, Dónal Landers, Paul Frewer, Nigel Brooks, Fabrice André	115
6	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer 2017 ·Molecular Cancer Therapeutics ·Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiří Tomášek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, Charles S. Fuchs	34
7	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial 2017 ·European Journal of Cancer ·David Ferry, Lucinda Billingham, Hugh Jarrett, David J. Dunlop, Penella J. Woll, M. Nicolson, Riyaz Shah, Joyce Thompson, James Spicer, D. Muthukumar, G. Skailes, Pauline Leonard, A.D. Chetiyawardana, Paula Wells, C. Lewanski, Barbara Crosse, (unknown), Piers Gaunt, Kenneth J. O’Byrne	15
8	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer 2015 ·JNCI Journal of the National Cancer Institute ·Francesco Sclafani, Tae‐Yop Kim, David Cunningham, Tae W. Kim, Josep Tabernero, Hans‐Joachim Schmoll, Jae Kyung Roh, Sun Kim, Young Shin Park, Tormod Kyrre Guren, Eliza A. Hawkes, (unknown), David Ferry, Jan‐Erik Frödin, Mark Ayers, Michael Nebozhyn, Clare Peckitt, Andrey Loboda, David J. Mauro, David Watkins	73
9	Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study 2014 ·PLoS ONE ·Dean A. Fennell, Scott P. Myrand, Tuan S. Nguyen, David Ferry, Keith M. Kerr, Perry Maxwell, Stephen D. Moore, Carla Visseren‐Grul, Mayukh Das, M. Nicolson	9
10	Time Course of Adverse Events in the Velour Trial 2013 ·Annals of Oncology ·David Ferry, Paul Ruff, Radek Lakomý, Jana Prausová, Guy van Hazel, (unknown), (unknown), (unknown), Eric Van Cutsem, Teresa Macarulla	1
11	Observed Benefit of Aflibercept in MCRC Patients ≥65 Years Old: Results of a Prespecified Age-Based Analysis of the Velour Study 2013 ·Annals of Oncology ·Paul Ruff, David Ferry, Demetris Papamichael, Radek Lakomý, Jana Prausová, Guy van Hazel, (unknown), Karen Soussan-Lazard, Pankaj Bhargava, Eric Van Cutsem, Teresa Macarulla	4
12	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial 2013 ·Journal of Thoracic Oncology ·M. Nicolson, Dean A. Fennell, David Ferry, Kenneth J. O’Byrne, Riyaz Shah, Vanessa Potter, G. Skailes, Sunil Upadhyay, Paul Taylor, Valérie André, Tuan S. Nguyen, Scott P. Myrand, Carla Visseren‐Grul, Mayukh Das, Keith M. Kerr	49
13	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen breakdown → 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra	986
14	Use of bevacizumab in the treatment of metastatic colorectal cancer 2012 ·British Journal of Hospital Medicine ·Sherif Raouf, John Bridgewater, Richard Ellis, David Ferry, Mark Hill, Harpreet Wasan	1
15	Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial 2009 ·JNCI Journal of the National Cancer Institute ·Siow Ming Lee, Penella J. Woll, Robin Rudd, David Ferry, Mary O’Brien, Gary Middleton, Stephen Spiro, Lindsay E. James, (unknown), Mark Jitlal, Allan Hackshaw	95
16	Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction 2006 ·Brachytherapy ·(unknown), Kent E. Wallner, (unknown), David Ferry, Kenneth Jutzy, Gary P. Foster	43
17	Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy 1999 ·Survey of Anesthesiology ·William E. Boden, Robert A. O’Rourke, Michael H. Crawford, Alvin Blaustein, Prakash Deedwania, Robert G. Zoble, Laura Wexler, Robert E. Kleiger, Carl J. Pepine, David Ferry, Bruce K. Chow	236
18	The Genetic Basis of Resistance to Cancer Chemotherapy 1995 ·Annals of Medicine ·(unknown), David Ferry	24
19	Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells 1994 ·European Journal of Pharmacology Molecular Pharmacology ·(unknown), David Ferry, Rainer Boer, Volker Gekeler, W Ise, (unknown)	27
20	Resolving the structure of the Ca2+ channel by photoaffinity labelling 1987 ·Trends in Pharmacological Sciences ·Hartmut Glossmann, David Ferry, Jörg Striessnig, A. Göll, (unknown)	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact